2.8 million+
antibiotic-resistant infections occur each year in the United States, resulting in the deaths of more than 35,000 Americans, according to the CDC’s updated estimates in 2019.
$4.8 billion+
in medical costs were caused by a subset of resistant infections in 2017, estimated the CDC.
38%
decline occurred between 2015 and 2018 in medically important antibiotics sold for use in food-producing animals, reported the FDA in 2019.
18%
decrease occurred in the overall number of U.S. deaths from antibiotic-resistant infections from 2012 to 2017.
30%
decrease occurred in the number of U.S. deaths from resistant infections in hospitals as a result of efforts to prevent infections and control their spread.
20%
decrease in healthcare-associated antibiotic-resistant infections by 2025 is an objective for the CDC.
10%
decrease in community-acquired antibiotic-resistant infections by 2025 is an objective for the CDC.
10
new antibiotic resistance-related diagnostics projects across the U.S. Government by 2021, through funding or scientific or technical support, are an objective for ASPR/BARDA, CDC, FDA, NIH, ARS, and DoD.
100
new projects (e.g., grants, contracts, CARB-X awards) awards aimed at therapeutic discovery or development by 2024 are an objective for ASPR/BARDA.
Citation: NATIONAL ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA 2020-2025, October 2020, From the Federal Task Force on Combating Antibiotic-Resistant Bacteria, https://www.hhs.gov/sites/default/files/carb-national-action-plan-2020-2025.pdf
